

# DNA Methylation Signatures of Depressive Symptoms in Middle-aged and Elderly Persons

## Meta-analysis of Multiethnic Epigenome-wide Studies

Olivera Story Jovanova, PhD; Ivana Nedeljkovic, MD; Derek Spieler, MD; Rosie M. Walker, PhD; Chunyu Liu, PhD; Michelle Luciano, PhD; Jan Bressler, PhD; Jennifer Brody, BA; Amanda J. Drake, PhD; Kathryn L. Evans, PhD; Rahul Gondalia, MPH; Sonja Kunze, PhD; Brigitte Kuhnel, MSc; Jari Lahti, PhD; Rozenn N. Lemaitre, PhD; Riccardo E. Marioni, PhD; Brenton Swenson, MSc; Jayandra Jung Himali, PhD; Hongsheng Wu, PhD; Yun Li, PhD; Allan F. McRae, PhD; Tom C. Russ, PhD; James Stewart, MSc; Zhiying Wang, MSc; Guosheng Zhang, MSc; Karl-Heinz Ladwig, PhD; Andre G. Uitterlinden, PhD; Xiuqing Guo, PhD; Annette Peters, PhD; Katri Räikkönen, PhD; John M. Starr, PhD; Melanie Waldenberger, PhD; Naomi R. Wray, PhD; Eric A. Whitsel, MD; Nona Sotoodehnia, MD; Sudha Seshadri, MD; David J. Porteous, PhD; Joyce van Meurs, PhD; Thomas H. Mosley, PhD; Andrew M. McIntosh, PhD; Michael M. Mendelson, MD; Daniel Levy, MD; Lifang Hou, PhD; Johan G. Eriksson, PhD; Myriam Fornage, PhD; Ian J. Deary, PhD; Andrea Baccarelli, PhD; Henning Tiemeier, PhD; Najaf Amin, PhD

### Supplemental content

**IMPORTANCE** Depressive disorders arise from a combination of genetic and environmental risk factors. Epigenetic disruption provides a plausible mechanism through which gene-environment interactions lead to depression. Large-scale, epigenome-wide studies on depression are missing, hampering the identification of potentially modifiable biomarkers.

**OBJECTIVE** To identify epigenetic mechanisms underlying depression in middle-aged and elderly persons, using DNA methylation in blood.

**DESIGN, SETTING, AND PARTICIPANTS** To date, the first cross-ethnic meta-analysis of epigenome-wide association studies (EWAS) within the framework of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium was conducted. The discovery EWAS included 7948 individuals of European origin from 9 population-based cohorts. Participants who were assessed for both depressive symptoms and whole-blood DNA methylation were included in the study. Results of EWAS were pooled using sample-size weighted meta-analysis. Replication of the top epigenetic sites was performed in 3308 individuals of African American and European origin from 2 population-based cohorts.

**MAIN OUTCOMES AND MEASURES** Whole-blood DNA methylation levels were assayed with Illumina-Infinium Human Methylation 450K BeadChip and depressive symptoms were assessed by questionnaire.

**RESULTS** The discovery cohorts consisted of 7948 individuals (4104 [51.6%] women) with a mean (SD) age of 65.4 (5.8) years. The replication cohort consisted of 3308 individuals (2456 [74.2%] women) with a mean (SD) age of 60.3 (6.4) years. The EWAS identified methylation of 3 CpG sites to be significantly associated with increased depressive symptoms: cg04987734 ( $P = 1.57 \times 10^{-08}$ ;  $n = 11\,256$ ; *CDC42BPB* gene), cg12325605 ( $P = 5.24 \times 10^{-09}$ ;  $n = 11\,256$ ; *ARHGEF3* gene), and an intergenic CpG site cg14023999 ( $P = 5.99 \times 10^{-08}$ ;  $n = 11\,256$ ; chromosome = 15q26.1). The predicted expression of the *CDC42BPB* gene in the brain (basal ganglia) (effect, 0.14;  $P = 2.7 \times 10^{-03}$ ) and of *ARHGEF3* in fibroblasts (effect, -0.48;  $P = 9.8 \times 10^{-04}$ ) was associated with major depression.

**CONCLUSIONS AND RELEVANCE** This study identifies 3 methylated sites associated with depressive symptoms. All 3 findings point toward axon guidance as the common disrupted pathway in depression. The findings provide new insights into the molecular mechanisms underlying the complex pathophysiology of depression. Further research is warranted to determine the utility of these findings as biomarkers of depression and evaluate any potential role in the pathophysiology of depression and their downstream clinical effects.

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Henning Tiemeier, PhD, Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, the Netherlands (h.tiemeier@erasmusmc.nl).

JAMA Psychiatry. 2018;75(9):949-959. doi:10.1001/jamapsychiatry.2018.1725  
Published online July 11, 2018. Corrected on August 22, 2018.

Depression is one of the most common mental health disorders that is projected to play a leading role in disease burden by 2030.<sup>1</sup> In later life, depression is associated with disability, increased mortality, dementia, and poor outcomes from physical illness.<sup>2</sup> Furthermore, more people older than 65 years commit suicide than in any other age group, and most have major depression.<sup>3</sup> Limited understanding of the molecular mechanisms underlying depression is a hindrance in the development of innovative treatment, prognostic markers, and prevention strategies.

Studying depression is challenging because it is a heterogeneous disorder with a multifactorial etiology.<sup>4</sup> This heterogeneity increases with age as the incidence of chronic diseases and disability rises. The contribution of genetics to the risk of depression is moderate, with heritability estimates ranging from 40% to 50%<sup>5</sup> and modest (18%) in the elderly.<sup>6</sup> Genome-wide association studies (GWAS) have identified numerous rare and common genetic variants associated with depression and related traits.<sup>7-10</sup> However, genetic variation alone does not completely explain an individual's risk for developing depression. Among environmental factors, adverse life events and stress are major risk factors for depression.<sup>11</sup> Converging evidence from animal and human studies suggests that psychosocial stressors trigger depression onset by inducing elevations in proinflammatory cytokine levels.<sup>12</sup> These psychosocial stressors are also known to influence epigenetic mechanisms, such as DNA methylation,<sup>13</sup> that can drive sustained changes in gene expression.<sup>14</sup> The high contribution of environmental factors to depression in the elderly makes DNA methylation a candidate mechanism for studies of the molecular basis of late-life depression.

DNA methylation may be global or tissue specific.<sup>15</sup> Tissues likely to be involved in complex psychiatric disorders, such as brain, are not directly accessible from living patients. The use of postmortem brain tissue to study DNA methylation is a possible solution, although obtaining a sufficient sample size is challenging.<sup>16</sup> To study differential DNA methylation associated with mental health symptoms on a large scale, peripheral tissues, such as blood, constitute a useful proxy for detecting trans-tissue changes and the most appropriate tissue for biomarkers.<sup>16,17</sup> Moderate correlation has been demonstrated between blood and brain tissues at nontissue-specific regulatory regions across the methylome.<sup>18</sup> To date, several studies have assessed the correlation between depression and DNA methylation.<sup>19,20</sup> However, these studies have been limited to a small number of DNA methylation sites (CpG sites) and/or small samples. For instance, the largest published epigenome-wide association study (EWAS) assessed brain DNA methylation in 76 persons who died during a depressive episode and 45 controls.<sup>21</sup> Moreover, these studies compared depressed cases with healthy controls. Depression represents an arbitrarily selected extreme of the continuum of varying severity and duration,<sup>22</sup> whereas a broad phenotype approach can be more representative for the general population. A large study consisting of 252 503 individuals from 68 countries showed that subthreshold depressive disorders produce significant decrements in health and do not qualitatively differ from full-blown episodes of depression.<sup>23</sup> A meta-analysis in

## Key Points

**Question** Can DNA methylation signatures of depressive symptoms be identified in blood samples in middle-aged and elderly persons in the general population?

**Findings** In this meta-analysis of epigenome-wide association studies of depressive symptoms comprising 11 256 participants of European and African origin from 11 population-based cohorts, 3 genomic sites were significantly associated with depressive symptoms. All 3 sites were either in genes or had downstream associations with genes expressed in the brain and converged to the axon guidance pathway.

**Meaning** This study suggests that robust DNA methylation signatures of depression are identifiable in blood and that these signatures may be similar across various races/ethnicities.

individuals older than 55 years found 2 to 3 times higher prevalence of subthreshold depressive symptoms than major depression.<sup>24</sup> Use of rating scales has therefore been recommended for the assessment of depressive problems in the elderly.<sup>2</sup>

In the present investigation, we performed an EWAS of depressive symptoms using whole-blood samples of 7948 individuals of European ethnicity from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. We replicated our findings in 3308 individuals of African American and European ancestry. Finally, we used publicly available expression quantitative methylation loci and expression quantitative loci databases to identify the downstream effects of the associated methylation loci.

## Methods

### Study Population

The study sample for the discovery analysis included a total of 7948 participants of European ancestry from 9 population-based cohorts of the CHARGE consortium (Table 1): Cardiovascular Health Study,<sup>25</sup> Framingham Heart Study,<sup>27</sup> Helsinki Birth Cohort Study,<sup>29</sup> Cooperative Health Research in the Augsburg Region study,<sup>30</sup> 2 subcohorts from Lothian Birth Cohort (LBC) born in 1921 (LBC1921)<sup>32</sup> and 1936 (LBC1936),<sup>34</sup> 2 subcohorts from Rotterdam Study (RS-III and RS-BIOS),<sup>35</sup> and Generation Scotland: Scottish Family Health Study study.<sup>36</sup> These cohorts included community-dwelling individuals who were not selected based on disease status. Informed consent was obtained from all participants. The same cohorts have been used successfully to identify differentially methylated sites associated with cognitive traits,<sup>42</sup> inflammation,<sup>43</sup> and smoking.<sup>44</sup> The protocol for each study was approved by the institutional review board of each institution.

The replication sample included 3308 participants, largely of African American origin from the Atherosclerosis Risk in Communities Study<sup>38</sup> and European origin from the Women's Health Initiative-Epigenetic Mechanisms of PM-Mediated Cardiovascular Disease that joined the consortium

Table 1. Descriptive Statistics of the Discovery and Replication Cohorts

Study	Ethnicity	No.	Women, No. (%)	Age, Mean (SD), y	Current Smoker, No. (%)	Depressive Symptoms (No. of Scale Items)	Antidepressant Medication Use, No. (%)
<b>Discovery (n = 7948)</b>							
CHS <sup>25</sup>	European	323	194 (60.1)	75.6 (5.2)	173 (53.6)	CES-D <sup>26</sup> (10)	19 (5.9)
FHS <sup>27</sup>	European	2722	1460 (53.6)	58.5 (11.6)	948 (34.8)	CES-D <sup>28</sup> (20)	251 (9.2)
HBCS <sup>29</sup>	European	122	0	65.2 (2.7)	24 (19.7)	CES-D <sup>28</sup> (20)	11 (9.0)
KORA <sup>30</sup>	European	1727	882 (51.1)	61.0 (8.9)	250 (14.5)	PHQ-9 <sup>31</sup>	82 (4.7)
LBC1921 <sup>32</sup>	European	432	261 (60.4)	79.1 (0.6)	194 (44.9)	HADS <sup>33</sup>	15 (3.5)
LBC1936 <sup>34</sup>	European	916	452 (49.3)	69.6 (0.8)	504 (55.0)	HADS <sup>33</sup>	30 (3.3)
RS-III <sup>35</sup>	European	722	391 (54.2)	59.8 (8.1)	167 (23.1)	CES-D <sup>28</sup> (20)	38 (5.3)
RS-BIOS <sup>35</sup>	European	757	319 (42.1)	67.6 (5.9)	78 (10.3)	CES-D <sup>28</sup> (20)	51 (6.7)
GS <sup>36a</sup>	European	227	145 (63.9)	52.4 (8.1)	46 (20.3)	SCID <sup>37</sup>	37 (16.3)
Total		7948	4104 (51.6)	65.4 (5.8)	2384 (30.0)		534 (6.7)
<b>Replication (n = 3308)</b>							
ARIC <sup>38</sup>	African	2297	1445 (62.9)	56.1 (5.7)	584 (25.4)	21-MQ <sup>39</sup>	74 (3.2)
WHI-EMPC <sup>40</sup>	European	1011	1011 (100)	64.6 (7.1)	509 (50.3)	CES-D/DIS <sup>41</sup>	61 (6.0)
Total		3308	2456 (74.2)	60.3 (6.4)	1093 (33.0)		135 (4.1)

Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; CES-D/DIS, Centre for Epidemiologic Studies Depression scale/Diagnostic Interview Schedule; CHS, Cardiovascular Health Study; FHS, Framingham Heart Study; GS, Generation Scotland; Scottish Family Health Study; HADS, Hospital Anxiety and Depression Scale-Depression Subscale; HBCS, Helsinki Birth Cohort Study; KORA, Cooperative Health Research in the Augsburg Region;

LBC, Lothian Birth Cohort; MQ, Maastricht Questionnaire; PHQ, Patient Health Questionnaire; RS, Rotterdam Study; SCID, Structured Clinical Interview for DSM-IV Disorders; WHI-EMPC, Women's Health Initiative-Epigenetic Mechanisms of PM-Mediated Cardiovascular Disease.

<sup>a</sup> Case-control study.

later for the replication phase of the study.<sup>40</sup> Detailed information for each cohort is provided in the eAppendix in the Supplement.

#### Depressive Symptoms Assessment

Depressive symptoms were measured using self-reported questionnaires or structured interviews performed by a trained researcher, psychologist, or psychiatrist at the same time when blood samples were obtained for DNA methylation quantification (Table 1).<sup>26,28,31,33,37,39,41</sup> Four cohorts (Framingham Heart Study, Helsinki Birth Cohort Study, RS-III, and RS-BIOS) assessed depressive symptoms using the 20-item Centre for Epidemiologic Studies Depression (CES-D) scale,<sup>45</sup> and the Cardiovascular Health Study used the 10-item CES-D scale. Participants could score from 0 to 60 (or 30 for Cardiovascular Health Study) points, where higher scores suggest more depressive symptoms. Women's Health Initiative-Epigenetic Mechanisms of PM-Mediated Cardiovascular Disease used a cohort-specific instrument that combines 6 items from the CES-D scale and 2 items from the Diagnostic Interview Schedule. The score on this instrument ranges from 0 to 1, with a higher score indicating a greater likelihood of depression. The LBC1921 and LBC1936 assessed self-reported depressive symptoms using the Hospital Anxiety and Depression Scale-Depression Subscale,<sup>33</sup> which consists of 7 items (range, 0-21, where a higher score suggests more depressive symptoms). The Cooperative Health Research in the Augsburg Region study used the self-administered Patient Health Questionnaire<sup>31</sup> representing a depression module that scores each of the 9 DSM-IV criteria for depression from 0 to 3 (higher scores indicate greater severity). The Generation Scotland: Scottish Family Health Study

assessed life-time history of depression using the Structured Clinical Interview for DSM-IV Disorders.<sup>46</sup> The Atherosclerosis Risk in Communities Study assessed depressive symptoms using the 21-item Maastricht Questionnaire, with scores ranging from 0 to 42 (higher scores indicate more exhaustion). In all cohorts, depressive symptoms were analyzed as continuous variables, except for Generation Scotland: Scottish Family Health Study, which studied depression status as binary trait.

#### DNA Methylation Sample and Measurement

In all cohorts, DNA was extracted from whole blood and methylation levels were assessed (Illumina-Infinium Human Methylation 450K BeadChip; Illumina Inc) using standard manufacturer's protocols. The 450K array includes more than 450 000 CpGs and is enriched for genic regions, covering 99% of all genes. DNA methylation data preprocessing, including quality control and normalization, was conducted per cohort using study-specific methods. In all cohorts, DNA methylation levels were quantified as  $\beta$  values, which range from 0 to 1 and indicate the proportion of DNA strands in a sample methylated at a specific CpG. Detailed information about cohort-specific DNA extraction, bisulfite conversion, DNA methylation profiling, normalization, and quality control is described in the eAppendix in the Supplement.

#### Statistical Analysis

##### Epigenome-wide Association Analysis

In all cohorts, the association between depressive symptoms and CpG sites was assessed using linear regression analysis. In the regression analysis, DNA methylation  $\beta$  value at each

CpG site was specified as the dependent variable and the depressive symptoms or depression as the predictor of interest. Association analysis was adjusted for age,<sup>47</sup> sex,<sup>48</sup> smoking<sup>44</sup> (assessed at the time of blood sampling for methylation), methylation batch effects, white blood cell composition (imputed or directly measured), principal components estimated using genome-wide genotype data to control for population stratification, and familial relationships when required. Cohort-specific details of these analyses are provided in the eAppendix in the Supplement. Furthermore, sensitivity analysis was performed by adjusting the initial model for antidepressant medication use at the time of sample collection.

To pool the results from independent studies, we performed sample size-weighted meta-analysis in METAL.<sup>49</sup> We chose the sample size-weighted method because of the differences in the measurement scales of depressive symptoms across studies. A drawback of using the sample size-weighted method is that no pooled-effect estimates are generated. To obtain pooled-effect estimates, we additionally performed inverse variance-weighted meta-analysis for the top sites in cohorts that used the CES-D 20-item scale for the assessment of depressive symptoms. Any CpG sites missing in more than 3 of the participating cohorts were removed. In total, 484 516 probes were tested for association, giving a Bonferroni-corrected genome-wide significance threshold of  $0.05/484\,516 = 1.03 \times 10^{-7}$ . All CpG sites suggestive of association ( $P \leq 10^{-5}$ ) were tested for association in the independent replication cohorts using the same model as used in the discovery EWAS. Finally, a sample size-weighted meta-analysis was performed for all cohorts included in the discovery and replication phases in METAL. To evaluate the contribution of each study to the association results, we generated posterior probabilities of the effects in each study (*M*-values) using the METASOFT package.<sup>50</sup> *M*-value and forest plots for *z* scores were generated using custom-made scripts in R. For annotating CpG sites, we used the annotation provided by Illumina and the University of California Santa Cruz UCSC database (GRCh37/hg19).

#### Gene Expression Analyses

To evaluate the downstream effects of the 3 identified CpG sites in blood, we used the BIOS database to search for expression-quantitative methylation.<sup>51</sup> To evaluate whether the expression of the genes that either harbored or whose expression was associated with the significant CpG sites was associated with major depression (also smoking and inflammation to check specificity), we used the MetaXcan, version 0.50 package.<sup>52,53</sup> MetaXcan associates the expression of the genes with the phenotype by integrating functional data generated by large-scale efforts, such as genotype-tissue expression (GTEx) with that of the GWAS. MetaXcan is trained on transcriptome models in 44 human tissues from GTEx and is able to estimate their tissue-specific effect on phenotypes from GWAS. We used the GTEx-V6p-HapMap-2016-09-08 database and the publicly available GWAS data sets of major depression,<sup>54</sup> C-reactive protein,<sup>55</sup> and smoking,<sup>56</sup> which represent important potential confounders in the present study.

#### Causal Inference Analysis

To help infer causal associations, we studied the *cis* single-nucleotide polymorphisms (SNPs) identified by the BIOS consortium<sup>51</sup> as instrumental variables for the CpG sites as proposed by Relton and Davey Smith.<sup>57</sup> We checked the association of these *cis*-SNPs with depression, smoking, and inflammation in the published GWAS of these traits. Similarly, we checked whether the SNPs associated with inflammation (C-reactive protein levels),<sup>55</sup> smoking,<sup>56</sup> and depression<sup>7</sup> were associated with the identified CpG sites using the BIOS consortium database. We chose smoking and inflammation because these are highly correlated with both depression and DNA methylation and thus could influence the association between depression and DNA methylation.

## Results

The mean (SD) age in the discovery cohorts ranged from 52.4 (8.1) years in Generation Scotland: Scottish Family Health Study to 79.1 (0.57) years in LBC1921. Of the total discovery sample, 4104 (51.6%) were women. The replication cohort comprised 2456 (74.2%) women and had a mean age of 60.3 (6.4) years (Table 1).

#### Epigenome-wide Association Analysis

In the meta-analysis of depressive symptoms of European ancestry, we identified 1 CpG site on chromosome 14q32.32 (cg04987734, *CDC42BPB* [OMIM 614062];  $P = 4.93 \times 10^{-08}$ ;  $n = 7948$ ) that passed the Bonferroni threshold for significance (Table 2; eFigure 1 in the Supplement). Furthermore, suggestive association was observed at 19 additional CpG sites (Table 2). Adjusting for antidepressive medication use did not meaningfully change the results (eTable 1 in the Supplement). No inflation in the test statistic was observed ( $\lambda = 1.03$ ) (eFigure 2 in the Supplement). We tested all 20 CpG sites for association in the replication sample. The top CpG site from the discovery (cg04987734) showed nominal association ( $P < .05$ ;  $n = 3308$ ) with depressive symptoms in the validation data set (Table 2). In addition, significant association of a CpG site (cg12325605;  $P = 9.17 \times 10^{-05}$ ;  $n = 3308$ ) (Table 2) annotated to the *ARHGEF3* [OMIM 612115] gene with depressive symptoms was observed in the replication sample.

Meta-analysis of discovery and replication cohorts showed a significant association of both cg04987734 ( $P = 1.57 \times 10^{-08}$ ;  $n = 11\,256$ ) and cg12325605 ( $P = 5.24 \times 10^{-09}$ ;  $n = 11\,256$ ) with depressive symptoms (Table 2, Figure 1 and Figure 2). An additional intergenic CpG site (cg14023999;  $P = 5.99 \times 10^{-08}$ ;  $n = 11\,256$ ) at chromosome 15q26.1 locus showed genome-wide significant association with depressive symptoms (eTable 2, eFigure 3, and eFigure 4 in the Supplement). The independent contributions of each cohort to the association signals of the 3 CpGs are depicted in eFigure 5 in the Supplement and also provided in eTable 3 in the Supplement. For all 3 CpG sites, the association signals were not driven by a single cohort, but appeared to be linearly related to the sample size, suggesting stronger association in larger studies (eFigure 5 in the Supplement). Pooled-effect estimates in cohorts that used the CES-D

Table 2. Top DNA Methylation Sites Associated With Depressive Symptoms in the Discovery Epigenome-wide Association Studies

CpG Site ID	Chromosome	Location	Gene Symbol	P Value		
				Discovery (n = 7948)	Replication (n = 3308)	Meta-analysis (n = 11 256)
cg04987734	14	103415873	CDC42BPB	$4.93 \times 10^{-08}$	$4.82 \times 10^{-02}$	$1.57 \times 10^{-08}$
cg07012687	17	80195180	SLC16A3	$3.47 \times 10^{-07}$	$1.58 \times 10^{-01}$	$4.45 \times 10^{-06}$
cg08796240	16	70733832	VAC14	$7.43 \times 10^{-07}$	$2.56 \times 10^{-01}$	$1.80 \times 10^{-06}$
cg06096336	2	231989800	PSMD1; HTR2B	$8.06 \times 10^{-07}$	$3.01 \times 10^{-01}$	$2.51 \times 10^{-06}$
cg16745930	10	100220809	HPSE2	$1.34 \times 10^{-06}$	$4.01 \times 10^{-01}$	$6.26 \times 10^{-06}$
cg09849319	5	1494983	LPCAT1	$1.81 \times 10^{-06}$	$4.64 \times 10^{-01}$	$1.04 \times 10^{-04}$
cg17237086	22	40814966	MKL1	$3.44 \times 10^{-06}$	$2.51 \times 10^{-01}$	$6.10 \times 10^{-06}$
cg03985718	2	105924245	TGFBRAP1	$3.61 \times 10^{-06}$	$8.54 \times 10^{-01}$	$6.53 \times 10^{-05}$
cg21098005	20	44538605	PLTP	$4.36 \times 10^{-06}$	$9.60 \times 10^{-01}$	$1.01 \times 10^{-04}$
cg16466652	19	6271960	MLL1	$4.39 \times 10^{-06}$	$3.97 \times 10^{-01}$	$1.57 \times 10^{-05}$
cg07884764	11	64107517	CCDC88B	$5.03 \times 10^{-06}$	$9.99 \times 10^{-01}$	$1.25 \times 10^{-04}$
cg01541347	7	4729920	FOXP1	$5.64 \times 10^{-06}$	$3.77 \times 10^{-01}$	$8.46 \times 10^{-04}$
cg02341197	21	34185927	C21orf62	$5.84 \times 10^{-06}$	$2.02 \times 10^{-01}$	$6.80 \times 10^{-06}$
cg01947751	3	196728969	Intergenic	$6.23 \times 10^{-06}$	$6.63 \times 10^{-01}$	$3.68 \times 10^{-04}$
cg13747876	17	80195402	SLC16A3	$6.32 \times 10^{-06}$	$1.04 \times 10^{-01}$	$2.93 \times 10^{-06}$
cg12764201	1	105101123	CORT; APITD1	$7.15 \times 10^{-06}$	$7.20 \times 10^{-01}$	$7.29 \times 10^{-05}$
cg08295111	5	133866097	PHF15	$7.87 \times 10^{-06}$	$5.76 \times 10^{-01}$	$5.64 \times 10^{-04}$
cg18030453	3	45506216	LARS2	$9.16 \times 10^{-06}$	$3.87 \times 10^{-03}$	$1.20 \times 10^{-07}$
cg12325605	3	56810151	ARHGEF3	$9.62 \times 10^{-06}$	$9.17 \times 10^{-05}$	$5.24 \times 10^{-09}$
cg23282441	10	73533927	C10orf54; CDH23	$9.69 \times 10^{-06}$	$1.77 \times 10^{-01}$	$8.63 \times 10^{-06}$

scale suggest that a 1-unit increase in the CES-D score increases methylation by 0.05% at cg04987734, 0.04% at cg12325605, and 0.03% at cg14023999.

#### Gene Expression Analyses

There was a significant association between cg04987734 and increased expression of the *CDC42BPB* gene (false discovery rate,  $P = 7.7 \times 10^{-04}$ ;  $n = 2101$ ) and cg14023999 was significantly associated with decreased expression of *SEMA4B* (OMIM 617029) (false discovery rate,  $P = 4.7 \times 10^{-03}$ ;  $n = 2101$ ) in blood (eTable 4 in the Supplement). No significantly associated gene expression probes were identified for cg12325605 in blood. Furthermore, the predicted expression of the *CDC42BPB* gene in the brain (basal ganglia) (effect, 0.14;  $P = 2.7 \times 10^{-03}$ ) and of *ARHGEF3* in fibroblasts (effect,  $-0.48$ ;  $P = 9.8 \times 10^{-04}$ ) was associated with major depression (eTable 5 in the Supplement). No association was observed with either smoking or inflammation.

#### Blood and Brain Correlation


We checked the correlation between methylation in blood and various brain regions at the 3 identified sites using a web-based tool (BECon<sup>18</sup>) and a blood-brain DNA methylation comparison tool (<http://epigenetics.essex.ac.uk/bloodbrain/>). BECon showed correlation between blood and brain DNA methylation, for example, methylation at cg04987734 in the *CDC42BPB* gene was highly correlated ( $r = 0.81$ ) between blood and the Brodmann area 7 that spans the medial and lateral walls of the parietal cortex (eFigure 6 in the Supplement). Methylation at the other 2 sites was negatively correlated with methylation in the Brodmann area 10 that spans anterior prefrontal cortex (cg12325605,  $r = -0.39$ ; cg14023999,

$r = -0.42$ ), suggesting strong but reverse methylation patterns in blood and brain (eFigure 7 and eFigure 8 in the Supplement). However, the blood-brain DNA methylation comparison tool that contrasts DNA methylation between blood and prefrontal cortex, entorhinal cortex, superior temporal gyrus, and cerebellum showed only modest correlations. For instance, methylation in blood at cg04987734 showed the strongest correlation with methylation in superior temporal gyrus ( $r = 0.18$ ; <http://epigenetics.essex.ac.uk/bloodbrain/?probenamg=cg04987734>), while methylation in blood at cg12325605 (<http://epigenetics.essex.ac.uk/bloodbrain/?probenamg=cg12325605>) and cg14023999 (<http://epigenetics.essex.ac.uk/bloodbrain/?probenamg=cg14023999>) showed the strongest correlation with methylation in cerebellum ( $r = 0.16$ ;  $r = 0.19$ , respectively). Nevertheless, the findings from the 2 databases suggest some degree of correlation between methylation in blood and methylation in brain for the 3 identified CpG sites.

#### Causal Inference

In the BIOS database we identified 2 *cis*-SNPs for cg04987734, 4 *cis*-SNPs for cg12325605 (eTable 6 in the Supplement), and none for cg14023999. We took the most significant *cis*-SNP as the proxy for the CpG sites if available. For cg04987734, we used rs751837 as a proxy and for cg12325605 we used rs3821412 as a proxy (top *cis*-SNP rs9880418 was not available in the GWAS of depression, smoking, or inflammation). There was suggestive association between rs751837 and major depression ( $P = .07$ ; albeit in the opposite direction) (eTable 7 in the Supplement); rs3821412 was not associated with any of the 3 tested phenotypes. None of the SNPs associated with depression, inflammation, or smoking was associated with any of the 3 CpG sites.

Figure 1. Regional Association Plot for the Top DNA Methylation (CpG) Site cg04987734  $-\log_{10}$  P Value



On the top graph, the x-axis depicts the position in base pair (bp) (hg19) for the entire *CDC42BPB* gene region. The y-axis indicates the strength of association in terms of negative logarithm of the association P value. Each circle represents a CpG site. Red dashed line within the graph indicates the genome-wide significance threshold. The regulatory information and correlation matrix of other CpG sites in the region with the top hit are shown below the x-axis. Color


intensity marks the strength of the correlation and color indicates the direction of the correlation. The figure was made using web-based plotting tool and R-based package CoMET (<http://epigen.kcl.ac.uk/comet/>). Ensembl is a genome database resource (<http://ensemblgenomes.org/>). SNP indicates single-nucleotide polymorphism; UCSC, University of California Santa Cruz.

## Discussion

In this large-scale EWAS of depressive symptoms, we identified methylation at 3 CpG sites (cg04987734, cg12325605, and

cg14023999) associated with depressive symptoms in middle-aged and elderly persons. cg04987734 is annotated to the *CDC42BPB* gene, cg12325605 to the *ARHGEF3* gene, and cg14023999 lies in an intergenic region on chromosome 15q26.1 locus. The predicted expression of *CDC42BPB* and *ARHGEF3*

Figure 2. Regional Association Plot for the Top CpG Site cg12325605



On the top graph, the x-axis depicts the position in base pair (bp) (hg19) for the entire *ARHGEF3* gene region. The y-axis indicates the strength of association in terms of negative logarithm of the association *P* value. Each circle represents a CpG site. Red dashed line within the graph indicates the genome-wide significance threshold. The regulatory information and correlation matrix of

other CpG sites in the region with the top hit are shown below the x-axis. Color intensity marks the strength of the correlation and color indicates the direction of the correlation. The figure was made using web-based plotting tool and R-based package CoMET (<http://epigen.kcl.ac.uk/comet/>). SNP indicates single-nucleotide polymorphism; UCSC, University of California Santa Cruz.

genes associated with major depression in brain and fibroblasts, respectively.

*CDC42BPB* (CDC42 binding protein kinase beta) encodes a member of the serine/threonine protein kinase family, which is a downstream effector of CDC42 and plays a role in the regulation of cytoskeleton reorganization, cell migration, and regulation of neurite outgrowth<sup>58</sup>; *CDC42BPB* is highly expressed

in the brain (<https://www.proteinatlas.org/ENSG00000198752-CDC42BPB/tissue>). Hypermethylation of cg04987734 has been associated with increased expression of *CDC42BPB* in blood.<sup>51</sup> Methylation levels at this CpG site (cg04987734) were also previously associated with C-reactive protein levels in blood<sup>43</sup> and smoking.<sup>44</sup> In our study, however, we adjusted for smoking in the regression model; therefore, the association

between depression and DNA methylation of this CpG site may be independent of smoking habits. Also, our causal inference analyses provide no support for the possibility that smoking or inflammation explained the observed association with depressive symptoms or that the predicted expression of the gene showed an association with smoking or inflammation.

The *ARHGEF3* gene encodes for rho guanine nucleotide exchange factor 3 protein. The gene is highly expressed (<https://www.proteinatlas.org/ENSG00000163947-ARHGEF3/tissue>) in adrenal glands, brain, and uterus. Both *ARHGEF3* and *CDC42BPB* are coexpressed with several members of the rho subfamily (RHOA, RHOB, and RHOC) (eFigure 9 and eFigure 10 in the Supplement) of the rho guanosine triphosphatase family that also includes CDC42.<sup>59</sup> The rho family of guanosine triphosphatases is a family of small signaling G proteins involved in p75 neurotrophin receptor-mediated signaling<sup>60</sup> and semaphorin-signaling pathways.<sup>61</sup> p75 Neurotrophin receptor is a transmembrane receptor for neurotrophic factors of the neurotrophin family, which includes the brain-derived neurotrophic factor.<sup>62</sup> p75 Neurotrophin receptor is widely expressed in the developing central and peripheral nervous systems during the period of synaptogenesis and developmental cell death.<sup>63</sup> Both p75 neurotrophin receptor and semaphorins are implicated in axon guidance.<sup>64,65</sup> In this context, the third associated CpG site, cg14023999, that lies in an intergenic region on chromosome 15q26.1 is also relevant as it associated with decreased expression of the *SEMA4B* (OMIM 617029) gene in blood. *SEMA4B* (OMIM 617029) encodes for semaphorin 4B protein. *SEMA4B* is believed to function through a direct interaction with postsynaptic density protein PSD-95<sup>66</sup> to promote synapse maturation.<sup>66-68</sup> The knockdown of *SEMA4B* causes a decrease in  $\gamma$ -aminobutyric acid-ergic synapse number,<sup>67</sup> suggesting a role in the assembly of excitatory and inhibitory postsynaptic specializations.<sup>68</sup> Previously, cg14023999 was found to be significantly correlated with Parkinson disease<sup>69</sup> and a significant association of a CpG site in *SEMA4B* was observed in individuals with schizophrenia carrying the 22q11.2 deletion.<sup>70</sup> These findings point toward a functional role of *SEMA4B* in neuropsychiatric disorders. When comparing our findings with those of the previous EWAS of depression, we did not find an overlap. These studies were small (<100 individuals) and did not report reproducible results.<sup>20</sup>

#### Strengths and Limitations

To our knowledge, this is the largest EWAS of depressive symptoms reported to date. Our major strength is the sample size that enabled detection of a replicable epigenome-wide significant locus, which suggests that in blood, DNA methylation signatures associated with depression may be subtle and will require large samples to be detected.

However, this study has several limitations. First, the study was using peripheral blood tissue for DNA methylation profiling, as DNA methylation is known to be tissue specific.<sup>71</sup> Although peripheral blood is not considered to be the most relevant tissue for the pathophysiology of depression, some sites show correlated methylation profiles between tissues.<sup>15,71</sup> The

3 sites identified in our study show some degree of correlation between methylation in blood and various brain regions. Second, although replication in African American samples suggests that some depressive symptom-related differences in DNA methylation may be similar across races/ethnicities,<sup>72-74</sup> the replication may also have resulted in false-negatives owing to different genetic background. Third, in these analyses we mostly used quantitative measures of depressive symptoms. Quantitative endophenotypes provide powerful alternatives for several complex outcomes, for example, hypertension.<sup>75</sup> This is likely to be especially true for a trait such as depressive symptoms, for which the severity and duration of illness can be highly heterogeneous.<sup>22</sup> Genome-wide studies of depressive traits, using quantitative endophenotypes, have been suggested to improve statistical power.<sup>22</sup> However, the use of different phenotypic measures by different cohorts means that there may be some loss of statistical power owing to the heterogeneity in the phenotype assessment. Nevertheless, the top 3 sites in our study were robustly associated with depressive symptoms independent of the depressive symptom measure used.

Fourth, although we adjusted for potential confounders, the possibility of residual confounding cannot be excluded. Antidepressant medication indicates treated depression but itself may result in epigenetic modifications involved in depression pathophysiology.<sup>76</sup> Antidepressants can thus mediate or confound the association between DNA methylation and depression. However, in sensitivity analysis additionally adjusted for antidepressant medication, our results did not change. Fifth, most cohorts included in this EWAS were composed of elderly persons. The cause of depression is more heterogeneous in elderly people than in younger people and often hidden behind somatic symptoms, either because of somatization of the disorder or because of accentuation of symptoms of concomitant illness.<sup>77</sup> This heterogeneity may affect the generalizability of the results to younger populations. Finally, we made an attempt to disentangle cause and consequence using SNPs associated with the identified CpG sites and depression, inflammation, and smoking as instrumental variables. The results did not support a causative role, yet the association of the predicted gene expression of *CDC42BPB* in brain and *ARHGEF3* in fibroblasts with major depression does suggest a possible causal role of the regulatory effects of these genes.<sup>52</sup>

#### Conclusions

To our knowledge, we report the first EWAS of depressive symptoms. We identified and replicated association of 2 methylation sites in the genome with depressive symptoms. A third site was identified in the meta-analysis of discovery and replication cohorts, which requires further replication. All 3 findings point toward axon guidance as the common disrupted pathway in depression (<http://www.genome.jp/kegg/pathway/hsa/hsa04360.html>). Our findings provide new insights into the molecular mechanisms underlying the complex pathophysiology of depression.



## ARTICLE INFORMATION

**Accepted for Publication:** May 17, 2018.

**Correction:** This article was corrected on August 22, 2018, to fix an error in the author byline and in the end matter Affiliations.

**Published Online:** July 11, 2018.  
doi:10.1001/jamapsychiatry.2018.1725

**Author Affiliations:** Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (Story Jovanova, Nedeljkovic, Uitterlinden, Tiemeier, Amin); Institute of Epidemiology II, Helmholtz Zentrum München, Neuherberg, Germany (Spieler, Kunze, Kühnel, Ladwig, Peters, Waldenberger); Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie des Klinikums Rechts der Isar der Technischen Universität München, Munich, Germany (Spieler, Ladwig); Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, Edinburgh, United Kingdom (Walker, Luciano, Evans, Marioni, Russ, Starr, Porteous, McIntosh, Deary); Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom (Walker, Evans, Porteous); The Framingham Heart Study, Framingham, Massachusetts (Liu, Himali, Seshadri, Mendelson, Levy); The Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, Maryland (Liu, Mendelson, Levy); Boston University School of Public Health, Boston, Massachusetts (Liu, Himali); Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom (Luciano, Marioni, Deary); Human Genetics Center, University of Texas Health Science Center at Houston (Bressler, Wang, Fornage); Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle (Brody, Lemaitre, Swenson, Sotoodehnia); University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (Drake); Department of Epidemiology, University of North Carolina at Chapel Hill (Gondalia, Stewart, Whitsel); Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany (Kunze, Kühnel, Peters, Waldenberger); Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland (Lahti, Räikkönen); Institute for Public Health Genetics, School of Public Health, University of Washington, Seattle (Swenson); Boston University School of Medicine, Boston, Massachusetts (Himali, Seshadri); Computer Science and Networking, Wentworth Institute of Technology, Boston, Massachusetts (Wu); Department of Genetics, University of North Carolina at Chapel Hill (Li, Zhang); Department of Biostatistics, University of North Carolina at Chapel Hill (Li, Zhang); Department of Computer Science, University of North Carolina at Chapel Hill (Li, Zhang); Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia (McRae, Wray); Queensland Brain Institute, The University of Queensland, Brisbane, Australia (McRae, Wray); Alzheimer Scotland Dementia Research Centre, Edinburgh, United Kingdom (Russ, Starr); Centre for Dementia Prevention, University of Edinburgh,

Edinburgh, United Kingdom (Russ); Carolina Population Center, University of North Carolina at Chapel Hill (Stewart); Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands (Uitterlinden, van Meurs); The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, Harbor-University of California Los Angeles (UCLA) Medical Center (Guo); Department of Medicine, University of North Carolina at Chapel Hill (Whitsel); MIND Center, University of Mississippi Medical Center, Jackson (Mosley); Division of Psychiatry, The University of Edinburgh, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, United Kingdom (McIntosh); Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts (Mendelson); Feinberg School of Medicine, Northwestern University, Chicago, Illinois (Hou); Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland (Eriksson); Institute of Molecular Medicine, University of Texas Health Science Center at Houston (Fornage); Department of Environmental Health Sciences, Harvard T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts (Baccarelli); Department of Child and Adolescent Psychiatry, Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (Tiemeier); Department of Social and Behavioral Science, Harvard T. H. Chan School of Public Health, Boston, Massachusetts (Tiemeier).

**Author Contributions:** Drs Story Jovanova, Nedeljkovic, Spieler, Walker, Liu, and Luciano were equal contributors to the study. Drs Tiemeier and Amin had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Story Jovanova, Nedeljkovic, Räikkönen, Starr, McIntosh, Mendelson, Tiemeier, Amin.

**Acquisition, analysis, or interpretation of data:** Story Jovanova, Nedeljkovic, Spieler, Walker, Liu, Luciano, Bressler, Brody, Drake, Evans, Gondalia, Kunze, Kühnel, Lahti, Lemaitre, Marioni, Swenson, Himali, Wu, Li, McRae, Russ, Stewart, Wang, Zhang, Ladwig, Uitterlinden, Guo, Peters, Waldenberger, Wray, Whitsel, Sotoodehnia, Seshadri, Porteous, van Meurs, Mosley, McIntosh, Mendelson, Levy, Hou, Eriksson, Fornage, Deary, Baccarelli, Tiemeier, Amin.

**Drafting of the manuscript:** Story Jovanova, Spieler, Liu, Kunze, Stewart, Uitterlinden, Tiemeier, Amin.

**Critical revision of the manuscript for important intellectual content:** Story Jovanova, Nedeljkovic, Spieler, Walker, Luciano, Bressler, Brody, Drake, Evans, Gondalia, Kunze, Kühnel, Lahti, Lemaitre, Marioni, Swenson, Himali, Wu, Li, McRae, Russ, Wang, Zhang, Ladwig, Guo, Peters, Räikkönen, Starr, Waldenberger, Wray, Whitsel, Sotoodehnia, Seshadri, Porteous, van Meurs, Mosley, McIntosh, Mendelson, Levy, Hou, Eriksson, Fornage, Deary, Baccarelli, Amin.

**Statistical analysis:** Story Jovanova, Nedeljkovic, Walker, Liu, Luciano, Brody, Gondalia, Kunze, Kühnel, Lahti, Marioni, Swenson, Wu, Li, McRae, Wang, Zhang, Uitterlinden, Guo, Amin.

**Obtained funding:** Drake, Evans, Lemaitre, Peters, Räikkönen, Starr, Wray, Whitsel, Sotoodehnia, Seshadri, Porteous, van Meurs, Mosley, McIntosh, Levy, Deary, Baccarelli, Tiemeier.

**Administrative, technical, or material support:** Story

Jovanova, Drake, Lahti, Ladwig, Peters, Räikkönen, Whitsel, Mosley, McIntosh, Mendelson, Levy, Eriksson, Deary, Amin.

**Supervision:** Drake, Evans, Lahti, Li, Guo, Peters, Starr, Waldenberger, Whitsel, Hou, Deary, Tiemeier, Amin.

**Other-generated part of the methylation data (KORA):** Kunze.

**Conflict of Interest Disclosures:** None reported.

**Additional Contributions:** We acknowledge the essential role of the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) Consortium in development and support of this manuscript. CHARGE members include the Netherlands Rotterdam Study, Framingham Heart Study, Cardiovascular Health Study, the Helsinki Birth Cohort Study, Cooperative Health Research in the Augsburg Region, Lothian Birth Cohort, Generation Scotland Study, Atherosclerosis Risk in Communities Study, and the Women's Health Initiative-Epigenetic Mechanisms of PM-Mediated Cardiovascular disease. Detailed acknowledgments are included in the eAppendix in the Supplement.

## REFERENCES

- Lépine JP, Briley M. The increasing burden of depression. *Neuropsychiatr Dis Treat*. 2011;7(suppl 1):3-7.
- Rodda J, Walker Z, Carter J. Depression in older adults. *BMJ*. 2011;343:d5219. doi:10.1136/bmj.d5219
- Conwell Y, Duberstein PR, Cox C, Herrmann JH, Forbes NT, Caine ED. Relationships of age and Axis I diagnoses in victims of completed suicide: a psychological autopsy study. *Am J Psychiatry*. 1996;153(8):1001-1008. doi:10.1176/ajp.153.8.1001
- Hidaka BH. Depression as a disease of modernity: explanations for increasing prevalence. *J Affect Disord*. 2012;140(3):205-214. doi:10.1016/j.jad.2011.12.036
- Lohoff FW. Overview of the genetics of major depressive disorder. *Curr Psychiatry Rep*. 2010;12(6):539-546. doi:10.1007/s11920-010-0150-6
- Gatz M, Pedersen NL, Plomin R, Nesselroade JR, McClearn GE. Importance of shared genes and shared environments for symptoms of depression in older adults. *J Abnorm Psychol*. 1992;101(4):701-708. doi:10.1037/0021-843X.101.4.701
- Wray NR, Ripke S, Mattheisen M, et al; eQTLGen; 23andMe; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet*. 2018;50(5):668-681. doi:10.1038/s41588-018-0090-3
- CONVERGE consortium. Sparse whole-genome sequencing identifies two loci for major depressive disorder. *Nature*. 2015;523(7562):588-591. doi:10.1038/nature14659
- Hek K, Demirkan A, Lahti J, et al. A genome-wide association study of depressive symptoms. *Biol Psychiatry*. 2013;73(7):667-678. doi:10.1016/j.biopsych.2012.09.033
- Direk N, Williams S, Smith JA, et al. An analysis of two genome-wide association meta-analyses identifies a new locus for broad depression phenotype. *Biol Psychiatry*. 2017;82(5):322-329. doi:10.1016/j.biopsych.2016.11.013

11. Agid O, Kohn Y, Lerer B. Environmental stress and psychiatric illness. *Biomed Pharmacother*. 2000;54(3):135-141. doi:10.1016/S0753-3322(00)89046-0
12. Berk M, Williams LJ, Jacka FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? *BMC Med*. 2013; 11:200. doi:10.1186/1741-7015-11-200
13. Dahl C, Guldborg P. DNA methylation analysis techniques. *Biogerontology*. 2003;4(4):233-250. doi:10.1023/A:1025103319328
14. Rakyan VK, Blewitt ME, Druker R, Preis JJ, Whitelaw E. Metastable epialleles in mammals. *Trends Genet*. 2002;18(7):348-351. doi:10.1016/S0168-9525(02)02709-9
15. Lohk K, Modhukur V, Rajashekar B, et al. DNA methylome profiling of human tissues identifies global and tissue-specific methylation patterns. *Genome Biol*. 2014;15(4):r54. doi:10.1186/gb-2014-15-4-r54
16. Byrne EM, Carrillo-Roa T, Henders AK, et al. Monozygotic twins affected with major depressive disorder have greater variance in methylation than their unaffected co-twin. *Transl Psychiatry*. 2013; 3:e269. doi:10.1038/tp.2013.45
17. Latham KE. Stage-specific and cell type-specific aspects of genomic imprinting effects in mammals. *Differentiation*. 1995;59(5):269-282. doi:10.1046/j.1432-0436.1996.5950269.x
18. Edgar RD, Jones MJ, Meaney MJ, Turecki G, Kobor MS. BECon: a tool for interpreting DNA methylation findings from blood in the context of brain. *Transl Psychiatry*. 2017;7(8):e1187. doi:10.1038/tp.2017.171
19. Bakusic J, Schaufeli W, Claes S, Godderis L. Stress, burnout and depression: a systematic review on DNA methylation mechanisms. *J Psychosom Res*. 2017;92:34-44. doi:10.1016/j.jpsychores.2016.11.005
20. Januar V, Saffery R, Ryan J. Epigenetics and depressive disorders: a review of current progress and future directions. *Int J Epidemiol*. 2015;44(4): 1364-1387. doi:10.1093/ije/dyu273
21. Nagy C, Suderman M, Yang J, et al. Astrocytic abnormalities and global DNA methylation patterns in depression and suicide. *Mol Psychiatry*. 2015;20 (3):320-328. doi:10.1038/mp.2014.21
22. van der Sluis S, Posthuma D, Nivard MG, Verhage M, Dolan CV. Power in GWAS: lifting the curse of the clinical cut-off. *Mol Psychiatry*. 2013;18 (1):2-3. doi:10.1038/mp.2012.65
23. Ayuso-Mateos JL, Nuevo R, Verdes E, Naidoo N, Chatterji S. From depressive symptoms to depressive disorders: the relevance of thresholds. *Br J Psychiatry*. 2010;196(5):365-371. doi:10.1192/bjp.bp.109.071191
24. Meeks TW, Vahia IV, Lavretsky H, Kulkarni G, Jeste DV. A tune in "B minor" can "B major": a review of epidemiology, illness course, and public health implications of subthreshold depression in older adults. *J Affect Disord*. 2011;129(1-3):126-142. doi:10.1016/j.jad.2010.09.015
25. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. *Ann Epidemiol*. 1991;1(3):263-276. doi:10.1016/1047-2797(91)90005-W
26. Irwin M, Artin KH, Oxman MN. Screening for depression in the older adult: criterion validity of the 10-item Center for Epidemiological Studies Depression Scale (CES-D). *Arch Intern Med*. 1999; 159(15):1701-1704.
27. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham offspring study. *Am J Epidemiol*. 1979;110(3):281-290. doi:10.1093/oxfordjournals.aje.a112813
28. Radloff LS. The CES-D scale: a self report depression scale for research in general population. *Appl Psychol Meas*. 1977;1(3):385-401.
29. Eriksson JG, Forsén T, Tuomilehto J, Osmond C, Barker DJ. Early growth and coronary heart disease in later life: longitudinal study. *BMJ*. 2001;322 (7292):949-953. doi:10.1136/bmj.322.7292.949
30. Wichmann HE, Gieger C, Illig T, Group MKS; MONICA/KORA Study Group. KORA-gen—resource for population genetics, controls and a broad spectrum of disease phenotypes. *Gesundheitswesen*. 2005;67(suppl 1):S26-S30. doi:10.1055/s-2005-858226
31. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606-613. doi:10.1046/j.1525-1497.2001.016009606.x
32. Deary IJ, Gow AJ, Pattie A, Starr JM. Cohort profile: the Lothian Birth Cohorts of 1921 and 1936. *Int J Epidemiol*. 2012;41(6):1576-1584. doi:10.1093/ije/dyr197
33. Zigmund AS, Snaith RP. The Hospital Anxiety And Depression Scale. *Acta Psychiatr Scand*. 1983; 67(6):361-370. doi:10.1111/j.1600-0447.1983.tb09716.x
34. Deary IJ, Gow AJ, Taylor MD, et al. The Lothian Birth Cohort 1936: a study to examine influences on cognitive ageing from age 11 to age 70 and beyond. *BMC Geriatr*. 2007;7:28. doi:10.1186/1471-2318-7-28
35. Ikram MA, Brusselle GGO, Murad SD, et al. The Rotterdam Study: 2018 update on objectives, design and main results. *Eur J Epidemiol*. 2017;32 (9):807-850. doi:10.1007/s10654-017-0321-4
36. Smith BH, Campbell A, Linksted P, et al. Cohort profile: Generation Scotland: Scottish Family Health Study (GS:SFHS): the study, its participants and their potential for genetic research on health and illness. *Int J Epidemiol*. 2013;42(3):689-700. doi:10.1093/ije/dys084
37. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P) November 2002.
38. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives: the ARIC investigators. *Am J Epidemiol*. 1989;129(4):687-702. doi:10.1093/oxfordjournals.aje.a115184
39. Watanakit K, Folsom AR, Chambless LE, Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J*. 2005;149(4):606-612.
40. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. *Control Clin Trials*. 1998; 19(1):61-109. doi:10.1016/S0197-2456(97)00078-0
41. Burnam MA, Wells KB, Leake B, Landsverk J. Development of a brief screening instrument for detecting depressive disorders. *Med Care*. 1988;26 (8):775-789.
42. Marioni RE, McRae AF, Bressler J, et al. Meta-analysis of epigenome-wide association studies of cognitive abilities. [published online January 8, 2018]. *Mol Psychiatry*. 2018. doi:10.1038/s41380-017-0008-y
43. Ligthart S, Marzi C, Aslibekyan S, et al; WHI-EMPC Investigators; CHARGE epigenetics of Coronary Heart Disease. DNA methylation signatures of chronic low-grade inflammation are associated with complex diseases. *Genome Biol*. 2016;17(1):255. doi:10.1186/s13059-016-1119-5
44. Joehanes R, Just AC, Marioni RE, et al. Epigenetic signatures of cigarette smoking. *Circ Cardiovasc Genet*. 2016;9(5):436-447. doi:10.1161/CIRCGENETICS.116.001506
45. Lewinsohn PM, Seeley JR, Roberts RE, Allen NB. Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. *Psychol Aging*. 1997;12(2):277-287. doi:10.1037/0882-7974.12.2.277
46. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; November 2002.
47. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol*. 2013;14(10):R115. doi:10.1186/gb-2013-14-10-r115
48. Singmann P, Shem-Tov D, Wahl S, et al. Characterization of whole-genome autosomal differences of DNA methylation between men and women. *Epigenetics Chromatin*. 2015;8:43. doi:10.1186/s13072-015-0035-3
49. Willer CJ, Li Y, Abecasis GR, METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010;26(17):2190-2191. doi:10.1093/bioinformatics/btq340
50. Han B, Eskin E. Interpreting meta-analyses of genome-wide association studies. *PLoS Genet*. 2012;8(3):e1002555. doi:10.1371/journal.pgen.1002555
51. Bonder MJ, Luijk R, Zhermakova DV, et al; BIOS Consortium. Disease variants alter transcription factor levels and methylation of their binding sites. *Nat Genet*. 2017;49(1):131-138. doi:10.1038/ng.3721
52. Barbeira A, Dickinson SP, Torres JM, et al. Integrating tissue specific mechanisms into GWAS summary results [published online February 17, 2017]. *bioRxiv*. doi:10.1101/045260
53. Gamazon ER, Wheeler HE, Shah KP, et al; GTEx Consortium. A gene-based association method for mapping traits using reference transcriptome data. *Nat Genet*. 2015;47(9):1091-1098. doi:10.1038/ng.3367
54. Ripke S, Wray NR, Lewis CM, et al; Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. A mega-analysis of genome-wide association studies for major depressive disorder. *Mol Psychiatry*. 2013;18(4): 497-511. doi:10.1038/mp.2012.21
55. Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. *Circulation*. 2011;123(7): 731-738. doi:10.1161/CIRCULATIONAHA.110.948570
56. Tobacco GC; Tobacco and Genetics Consortium. Genome-wide meta-analyses identify

- multiple loci associated with smoking behavior. *Nat Genet.* 2010;42(5):441-447. doi:10.1038/ng.571
57. Relton CL, Davey Smith G. Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease. *Int J Epidemiol.* 2012;41(1):161-176. doi:10.1093/ije/dyr233
58. Chen XQ, Tan I, Leung T, Lim L. The myotonic dystrophy kinase-related Cdc42-binding kinase is involved in the regulation of neurite outgrowth in PC12 cells. *J Biol Chem.* 1999;274(28):19901-19905. doi:10.1074/jbc.274.28.19901
59. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. *Nature.* 2002;420(6916):629-635. doi:10.1038/nature01148
60. DeGeer J, Lamarche-Vane N. Rho GTPases in neurodegeneration diseases. *Exp Cell Res.* 2013;319(15):2384-2394. doi:10.1016/j.yexcr.2013.06.016
61. Liu BP, Strittmatter SM. Semaphorin-mediated axonal guidance via rho-related G proteins. *Curr Opin Cell Biol.* 2001;13(5):619-626. doi:10.1016/S0955-0674(00)00260-X
62. Woo NH, Teng HK, Siao CJ, et al. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. *Nat Neurosci.* 2005;8(8):1069-1077. doi:10.1038/nn1510
63. Davies AM. Nerve growth factor synthesis and nerve growth factor receptor expression in neural development. *Int Rev Cytol.* 1991;128:109-138. doi:10.1016/S0074-7696(08)60498-2
64. Fiore R, Püschel AW. The function of semaphorins during nervous system development. *Front Biosci.* 2003;8:s484-s499. doi:10.2741/1080
65. Schecterson LC, Bothwell M. An all-purpose tool for axon guidance. *Sci Signal.* 2008;1(47):pe50. doi:10.1126/scisignal.147pe50
66. Burkhardt C, Müller M, Badde A, Garner CC, Gundelfinger ED, Püschel AW. Semaphorin 4B interacts with the post-synaptic density protein PSD-95/SAP90 and is recruited to synapses through a C-terminal PDZ-binding motif. *FEBS Lett.* 2005;579(17):3821-3828. doi:10.1016/j.febslet.2005.05.079
67. Paradis S, Harrar DB, Lin Y, et al. An RNAi-based approach identifies molecules required for glutamatergic and GABAergic synapse development. *Neuron.* 2007;53(2):217-232. doi:10.1016/j.neuron.2006.12.012
68. Pasterkamp RJ, Giger RJ. Semaphorin function in neural plasticity and disease. *Curr Opin Neurobiol.* 2009;19(3):263-274. doi:10.1016/j.conb.2009.06.001
69. Chuang YH, Paul KC, Bronstein JM, Bordelon Y, Horvath S, Ritz B. Parkinson's disease is associated with DNA methylation levels in human blood and saliva. *Genome Med.* 2017;9(1):76. doi:10.1186/s13073-017-0466-5
70. Starnawska A, Hansen CS, Sparsø T, et al. Differential DNA methylation at birth associated with mental disorder in individuals with 22q11.2 deletion syndrome. *Transl Psychiatry.* 2017;7(8):e1221. doi:10.1038/tp.2017.181
71. Bagot RC, Labonté B, Peña CJ, Nestler EJ. Epigenetic signaling in psychiatric disorders: stress and depression. *Dialogues Clin Neurosci.* 2014;16(3):281-295.
72. Klengel T, Pape J, Binder EB, Mehta D. The role of DNA methylation in stress-related psychiatric disorders. *Neuropharmacology.* 2014;80:115-132. doi:10.1016/j.neuropharm.2014.01.013
73. Galanter JM, Gignoux CR, Oh SS, et al. Differential methylation between ethnic sub-groups reflects the effect of genetic ancestry and environmental exposures. [published online January 3, 2017]. *Elife.* 2017;6:e20532. doi:10.7554/eLife.20532
74. Kader F, Ghai M. DNA methylation-based variation between human populations. *Mol Genet Genomics.* 2017;292(1):5-35. doi:10.1007/s00438-016-1264-2
75. Ehret GB, Munroe PB, Rice KM, et al; International Consortium for Blood Pressure Genome-Wide Association Studies; CARDIoGRAM Consortium; CKDGen Consortium; KidneyGen Consortium; EchoGen Consortium; CHARGE-HF Consortium. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature.* 2011;478(7367):103-109. doi:10.1038/nature10405
76. Lisoway AJ, Zai CC, Tiwari AK, Kennedy JL. DNA methylation and clinical response to antidepressant medication in major depressive disorder: a review and recommendations. *Neurosci Lett.* 2018;669:14-23. doi:10.1016/j.neulet.2016.12.071
77. Gottfries CG. Is there a difference between elderly and younger patients with regard to the symptomatology and aetiology of depression? *Int Clin Psychopharmacol.* 1998;13(suppl 5):S13-S18. doi:10.1097/00004850-199809005-00004